WHAT DOES PET IMAGING ADD TO CONVENTIONAL STAGING OF HEAD AND NECK CANCER PATIENTS?
|
|
- Frederick Clifford Elliott
- 5 years ago
- Views:
Transcription
1 doi: /j.ijrobp Int. J. Radiation Oncology Biol. Phys., Vol. 68, No. 2, pp , 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved /07/$ see front matter CLINICAL INVESTIGATION Head and Neck WHAT DOES PET IMAGING ADD TO CONVENTIONAL STAGING OF HEAD AND NECK CANCER PATIENTS? SURJEET POHAR, M.D.,* ROBERT BROWN, B.S.,* NANCY NEWMAN, M.S., MICHAEL KONIARCZYK,* JACK HSU, M.D., AND DAVID FEIGLIN, M.D. Departments of *Radiation Oncology, Otolaryngology, Radiology, and Medicine, SUNY Upstate Medical University, Syracuse, NY; Department of Radiation Oncology, Eastern Virginia Medical School, Norfolk, VA Purpose: To determine the value of PET scans in the staging of patients with head and neck carcinoma. Methods and Materials: The charts of 25 patients who underwent neck dissection, computed tomography (CT) scan, and F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging as part of their initial work-up for a head and neck squamous cell cancer between were reviewed. All patients underwent clinical examination, triple endoscopy, and chest radiograph as part of their clinical staging, adhering to American Joint Commission for Cancer criteria. In addition to the clinical nodal (N) stage, PET findings were incorporated to determine a second type of N staging: clinical N PET stage. The number of neck sides and nodal involved on CT or PET and on pathologic examination were recorded. Results: The sensitivity and specificity for detection of nodal disease were similar for CT and FDG-PET. Positive and negative likelihood ratios were similar for both diagnostic tests. None of our 25 patients had unsuspected distant disease detected by PET. Conclusion: The addition of PET imaging did not improve diagnostic accuracy in our patients compared with CT. PET scanning did not alter clinical management in any of the patients Elsevier Inc. PET imaging, Head and neck carcinoma. INTRODUCTION F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) imaging is frequently used in patients with squamous cell carcinoma of the head and neck (SCCHN). Some studies have suggested that PET changes the extent of disease in 15% 20% of patients with head and neck cancer compared with computed tomography (CT) alone (1, 2). In 2001, Schecter et al. reviewed the literature and concluded that FDG-PET adds little to conventional imaging studies for the pretreatment detection of nodal metastases, detection of unknown primaries, or metastatic disease in the chest (3). Gregoire states that the staging of the head and neck nodes is a very good illustration of the uselessness of FDG-PET for target volume selection and delineation in the neck (4). Frank et al., however, suggest that the utilization of PET/CT is appropriate for head and neck cancer staging in the initial presentation (5). Thus, review articles discussing PET and CT/PET conclude that it is either a valuable modality in the initial evaluation of SCCHN or a useless modality (3 5). This study will attempt to define the incremental value of FDG-PET imaging for neck staging to conventional staging methods in surgically managed Reprint requests to: Surjeet Pohar, M.D., Department of Radiation Oncology, Eastern Virginia Medical School, 600 Gresham Drive, Norfolk, VA Tel: (757) ; poharss@evms.edu Presented at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), November patients with SCCHN. The endpoints to be examined in this study include diagnostic sensitivity, specificity, and accuracy of CT vs. FDG-PET for neck nodal metastases. The imaging findings were compared with the gold standard: pathologic findings from neck dissection. METHODS AND MATERIALS Patients The charts of 25 patients who had CT and PET for staging SCCHN followed by neck dissection from were reviewed. A total of 38 neck sides were dissected in these 25 patients. Twenty-one patients had definitive surgery for their primary SCCHN. Neck dissections were divided into anatomic 1 5 using standard criteria by the operating surgeon. Clinical staging included history and physical examination, routine laboratory tests, and triple endoscopy in all patients. The study was approved by the Institutional Review Board of SUNY Upstate Medical University. CT scans The CT scans were contrast enhanced and done on several different scanners and interpreted by many radiologists without 5 9, 2006, Philadelphia, PA. Conflict of interest: none. Received June 30, 2006, and in revised form Sept 16, Accepted for publication Dec 19,
2 384 I. J. Radiation Oncology Biology Physics Volume 68, Number 2, 2007 Table 1. Patient characteristics Age (median, in y) 63.4 No. of patients Sex Male 17 Female 8 Primary site Oral cavity 8 Oropharynx 8 Hypopharynx 2 Larynx 5 Nasal cavity 1 Unknown primary 1 Pathologic AJCC stage II 3 III 1 IVA 17 Unknown 4 Management Primary surgery 21 Neck dissection 25 Radiation therapy 22 Primary or adjuvant chemotherapy 5 any knowledge of the PET findings. From CT reports and scans, the first author determined the number of nodal and neck sides involved by disease. Similarly, the first author used operative reports and pathologic reports to determine the number of nodal dissected and the number of with metastatic involvement. PET scans The PET scans were done at 2 facilities and interpreted by several radiologists. Four of the 25 scans were CT/PET scans. The PET radiologist had access to the CT scans in about half of the cases. The first author used the nuclear medicine physician s report of area(s) of increased uptake to determine the number of nodal and neck sides involved by malignant disease. There was no specific standard uptake value (SUV) used to identify malignant disease. PET scan was performed using the following method: Advance PET scanner or Discovery ST PET/CT system was used. Both systems were made by General Electric Medical Systems (Chalfont St. Giles, UK) and utilize bismuth germanium oxide detector technology. Patients were administered 10 mci of F-18-FDG and PET imaging was performed in supine position in 2D mode. Transmission PET data were reconstructed using filtered back projection method, in matrix, pixel size 4.25 mm, with Hanning filter, cutoff at 8.5 mm, real-time random subtraction, and geometric correction. Emission PET data were reconstructed using the Table 2. Comparison of clinical N stage and clinical N stage PET in 25 patients Clinical N stage Clinical N stage PET True positive False negative (understage) 4 4 False positive (overstage) 4 4 True negative 4 4 Table 3. Comparison of nodal involvement on CT with pathologic involvement in 161 nodal CT Involved nodal Uninvolved nodal Pathologic involved nodal Pathologic negative nodal OS-EM iterative method, in matrix, pixel size correction was used, with Gaussian smoothing 8 mm, axial smoothing, and real-time random subtraction. Well counter used real-time random subtraction, geometric, decay, deadtime, and scatter correction. Staging Each patient was assigned a clinical nodal (N) stage by the first 2 authors according to the American Joint Commission on Cancer staging criteria, incorporating all clinical findings, as well as CT interpretation by the diagnostic radiologist. They also determined a clinical N PET stage for each patient by incorporating the nuclear medicine physician s findings. For example, if there was a 2-cm node on 1 neck side, the clinical N would be N1. If the PET was positive only at this site, clinical N PET would be N1. Clinical N PET would be N2 if another area was considered malignant in this neck; NO if the PET was read as normal for the neck. RESULTS Patient characteristics and treatment information are listed in Table 1. Most of the patients presented with locally advanced squamous cell carcinoma. Pathologic neck stage (pn) is compared with clinical N stage and clinical N PET stage in Table 2. The ability of each modality to determine neck nodal level involvement in the 161 dissected nodal is listed in Tables 3 and 4. PET and CT both show significant and identical positive correlation with pathologic neck findings in Tables 3 and 4. However, although the overall discordance of CT and PET with pathologic findings is identical, the discordance is not in the Table 4. Comparison of nodal involvement on PET with pathologic involvement in 161 nodal PET Involved nodal Uninvolved nodal Pathologic involved nodal Pathologic negative nodal Chi-square tests for Tables 3 and 4 indicate a p with 1 degree of freedom.
3 PET imaging and staging of cancer patients S. POHAR et al. 385 Table 5. CT vs. PET imaging results by neck side involvement Current series Neck sides dissected Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%) Accuracy (%) CT 38 15/19 (79) 16/19 (84) 15/18 (83) 16/20 (80) 24/33 (73) PET 38 15/21 (71) 14/17 (82) 15/18 (83) 14/20 (70) 24/33 (73) identical patients or nodal. McNemar-matched proportional testing of CT vs. PET to predict pathologic nodal level involvement shows no difference; relative risk 1.0. The median SUV of involved nodal is 5.8 with a range of Three of 18 positive neck sides on PET are falsely positive (pathologically negative) with SUVs of 2, 2.7, and 8, respectively. Six patients are discordant between clinical N and clinical N PET stage. The clinical N PET was identical to pathologic N in 3 of these 6 patients; clinical N (including CT findings) was identical to pathologic N in the other 3 patients. Table 5 lists results of CT vs. PET in correctly identifying malignant disease in a neck side. Each neck dissection, whether partial or complete, is counted as a neck side dissection. Each of the two imaging modalities has an accuracy of 73%. Unsuspected distant malignant disease was not found by PET in any of the 25 patients reviewed. DISCUSSION Vermeersch et al. published the most extensive review in the literature of the role of PET imaging in the staging of SCCHN (6). Their article includes an evaluation of 17 articles comparing CT/MRI with FDG-PET for SCCHN. Several of the articles compare MRI or ultrasound with FDG-PET, and most do not correlate neck side or nodal extent of involvement with pathology. Vermeersch et al. conclude that there was a significantly higher sensitivity and specificity with PET than CT/MRI for detection of nodal metastases (6). However, they also explicitly state that given the large variation in methods used by different authors to assess the presence or absence of disease, a straightforward meta-analysis of FDG-PET was not possible. For this study, the literature was reviewed for articles meeting the following criteria: (1) all patients had SC- CHN and a CT and PET scan for staging, (2) all patients had neck surgery and pathologic nodal examination as the reference standard, and (3) CT and PET were compared with pathologic examination for neck side involvement and/or nodal extent of involvement. Three articles met our criteria (7 9). Two were included in the analysis by Vermeersch et al. (7, 9). Jaeschke, Guyatt, and Sackett published criteria to guide readers to determine whether the findings in an article about a diagnostic test are valid (10). One of their criteria is that the diagnostic test (in this case CT or PET) should not influence the decision to perform the reference standard (neck dissection). Twenty-one patients in our study were treated with primary surgical intent for their primary disease, so the decision to do a neck dissection was driven by their primary disease, not the imaging findings. Four patients with unknown primary or SCCHN had neck dissection for clinically evident neck disease before radiation therapy. The neck imaging did not influence the decision to do a neck dissection. This series meets the criteria by Jaeschke et al. for valid data. The other three publications did not provide sufficient details to determine whether they meet these criteria. The four series differ in many respects. Two studies (7, 9) published by the same group of investigators were limited to squamous cell carcinomas of the oral cavity and palate. Schwartz et al. and this series included a variety of SCCHN, with a preponderance of locally advanced tumors (8). The series differed in patient numbers ranging from patients. Also, two series compare individual pathologic nodal findings with imaging results (7, 9), whereas the others compare nodal level findings on pathologic examination with imaging results (8). Furthermore, Schwartz et al. compared CT/PET with CT, and the other series compared PET and CT. Radiologists do not have standardized criterion to identify malignant neck disease, particularly with PET. The wide range of results is evident in Table 6; however, the average increase in accuracy by the addition of PET is about 5%. Among the series, Jaeschke et al. recommended using likelihood ratios to help determine whether the results of a diagnostic test will help in caring for patients (Table 7) (11). Positive likelihood ratios (LR ) are a ratio of posttest probability of disease vs. pretest probability of disease in a patient. The higher the ratio the better the test is at finding disease. Jaeschke et al. reported that positive likelihood ratios (LR ) 10 indicate the test often leads to conclusive changes in the probability of disease, whereas ratios 5 to 10 indicated moderate shifts in the probability of disease (11). Conversely, negative likelihood ratios (LR ) reflect the probability that disease is absent in a patient after the test compared with the probability before the test was done. The lower the ratio the more likely that the test is useful in detecting absence of disease. Jaeschke et al. reported that a LR 0.10 indicated a frequent conclusive change by the test in probability that disease is absent, while a ratio between 0.1 and 0.2 generated moderate shifts in probability and ratios between 0.2 and 0.5 lead to small shifts in probability that disease is absent (13). The
4 386 I. J. Radiation Oncology Biology Physics Volume 68, Number 2, 2007 Table 6. Analysis of CT vs. PET for neck disease by nodal level or nodal group involvement in 4 studies CT (Percentage) PET (Percentage) Sens (%) Spec (%) PPV (%) NPV (%) Acc (%) Sens (%) Spec (%) PPV (%) NPV (%) Acc (%) Series N No. LN Adams (8) Schwarz (9) Stuckensen (10) Current series Range of above Abbreviations: Sens sensitivity (The sensitivity of each imaging modality was determined by calculating the fraction of pathologically positive nodal or groups found by the imaging modality); Acc accuracy (Accuracy is simply the percentage of nodal groups or whose pathologic status was correctly identified by the imaging study); Spec specificity (Specificity was calculated as the fraction of nodal groups or negative on the imaging study compared to the number pathologically negative on neck dissection); NPV negative predictive value; PPV positive predictive value; No. LN number of lymph nodes or nodal pathologically examined. Table 7. Likelihood ratios of CT or PET in predicting the presence or absence of neck disease First author CT PET LR( ) LR( ) LR( ) LR( ) Adams (7) Schwartz (6) Stuckenson (9) Current series Abbreviations: LR( ) positive likelihood ratio: sens/(1- spec); LR( ) negative likelihood ratio: (1-sens)/spec. results of this analytic test on the four series are listed in Table 7. Adams et al. (7) was the only study where CT and PET were in different LR ranges using the criterion by Jaeschke s et al. (8). Thus, three of the four series suggested similar efficacy of PET and CT in identifying neck disease by nodal level or lymph node group. Adams et al. (7) found LR of CT showed it to result in small shift in probability that disease was absent (0.21), whereas PET led to a moderate shift that disease was absent (0.11). Schwartz et al. (6), however, reported that the LR of CT suggested a small shift in probability that disease was absent (0.22), and PET led to a frequent conclusive shift in probability of finding no disease in the neck (0.04). Stuckenson et al. (9) and our study show little difference in LR between CT and PET (Table 7). The trend observed in the analysis of these small series is that CT and PET are of similar efficacy in detecting the absence of neck disease. This study confirms that the SUV is of limited value in evaluating malignant nodal disease in SCCHN because there is considerable overlap in the range of values seen in benign false-positive nodes and malignant nodes. This finding was previously reported by Adams et al. (7), who found a SUV range of in benign inflammatory nodes and 2 11 in malignant nodes (8). Both CT and PET identify malignant nodal disease with high accuracy in SCCHN with similar false-positive and -negative ratios. If every 1 of the 39,250 SCCHN patients diagnosed annually has PET imaging as part of the initial staging work-up, the cost in the USA alone would be about $100 million (12, 13). A very large prospective study would be required to prove that PET improves accuracy by the 5% estimated by the other series in Table 6. The high costs of performing such a study might not be justifiable for a diagnostic tool like PET, which rarely changes clinical management, or not at all as in this study. PET may have a more important role to play in early detection of persistent disease, which is being further investigated in RTOG protocol 0522 or in identifying recurrent disease (14). Currently, PET imaging remains investigational in the staging of SCCHN.
5 PET imaging and staging of cancer patients S. POHAR et al. 387 REFERENCES 1. Kresnick E, Mikosch P, Gallowitsch H, et al. Evaluation of head and neck cancer with 18 F-FDG PET: A comparison with conventional methods. Eur J Nucl Med 2001;28: Sigg M, Steinert H, Gratz K, Hugenin P, Stoeckli S, Eyrich GK. Staging of head and neck tumors: 18 F fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities. J Oral Maxillofac Surg 2003;61: Schecter N, Gillenwater A, Byers R, et al. Can positron emission tomography improve the quality of care for head and neck cancer patients? Int J Radiat Oncol Biol Phys 2001;51: Gregoire V. Is there any future in radiotherapy planning without the use of PET: Unraveling the myth... Radiother Oncol 2004;73: Frank SJ, Chao KS, Schwartz DL, et al. Technology insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. Natl Clin Pract Oncol 2005;10: Vermeersch H, Loose D, Ham H, et al. Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers. Eur J Nucl Med Mol Imaging 2003;30: Adams S, Baum R, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18 F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25: Schwartz D, Ford E. Rajendran J,etal.FDG-PET/CT imaging for preradiotherapy staging of head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;61: Stuckensen T, Kovacs AF, Adams S, et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: A prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000;28: Jaeschke R, Guyatt G, Sackett D. Users guide to the medical literature-iii. How to use an article about a diagnostic test-b. Are the results of the study valid? JAMA 1994;271: Jaeschke R, Guyatt G, Sackett D. Users guide to the medical literature-iii. How to use an article about a diagnostic test-b. What are the results and will they help me in caring for my patients? JAMA 1994;271: Jemal A, Taylor M, Ward E, et al. Cancer Statistics CA Cancer J Clin 2005;55: Centers for Medicare and Medicaid Services, 2005 Fee Schedule, Upstate New York Division. Available at: umd.nycpic.com. 14. Wong RJ, Lin H, Schoder SG, et al. Diagnostic and prognostic value of [ 18 F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:
Dr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study
Official publication of Orofacial Chronicle,India www.jhnps.weebly.com ORIGINAL ARTICLE ROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study ABSTRACT: Akheel Mohammad 1, Anuj
More informationTHE COMPARISON OF THREE DIFFERENT MALIGNACY EVALUATION CRITERIA OF CERVICAL LYMPH NODES IN ORAL CAVITY CANCER USING F-18 FDG PET-CT
Acta Medica Mediterranea, 2015, 31: 183 THE COMPARISON OF THREE DIFFERENT MALIGNACY EVALUATION CRITERIA OF CERVICAL LYMPH NODES IN ORAL CAVITY CANCER USING F-18 FDG PET-CT ERDEM SÜRÜCÜ 1, YUSUF DEMIR 1,
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationComparative evaluation of oral cancer staging using PET-CT vs. CECT
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 5 (2015) pp. 1168-1175 http://www.ijcmas.com Original Research Article Comparative evaluation of oral
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationHEAD AND NECK SQUAMOUS
ORIGINAL ARTICLE The Role of Positron Emission Tomography and Computed Tomography Fusion in the Management of Early-Stage and Advanced-Stage Primary Head and Neck Squamous Cell Carcinoma Patrick K. Ha,
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationPositron emission tomography/computer tomography in the evaluation of head and neck cancer treatment
Positron emission tomography/computer tomography in the evaluation of head and neck cancer treatment Severina Šedienė 1, Ilona Kulakienė 1, Viktoras Rudžianskas 2 1 Lithuanian University of Health Sciences,
More informationPositron Emission Tomography in Lung Cancer
May 19, 2003 Positron Emission Tomography in Lung Cancer Andrew Wang, HMS III Patient DD 53 y/o gentleman presented with worsening dyspnea on exertion for the past two months 30 pack-year smoking Hx and
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More informationUtilisation du PET-FDG pour la définition des volumes cibles en radiothérapie des tumeurs de la sphère cervico-maxillo-faciale: mythe et réalité
Utilisation du PET-FDG pour la définition des volumes cibles en radiothérapie des tumeurs de la sphère cervico-maxillo-faciale: mythe et réalité Vincent GREGOIRE, M.D., Ph.D. Head and Neck Oncology Program,
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationBone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationRole of PETCT in the management of untreated advanced squamous cell carcinoma of the oral cavity, oropharynx and hypopharynx
International Journal of Otorhinolaryngology and Head and Neck Surgery Dutta A et al. Int J Otorhinolaryngol Head Neck Surg. 2018 Mar;4(2):526-531 http://www.ijorl.com pissn 2454-5929 eissn 2454-5937 Original
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationIAEA RTC. PET/CT and Planning of Radiation Therapy 20/08/2014. Sarajevo (Bosnia & Hercegovina) Tuesday, June :40-12:20 a.
IAEA RTC PET/CT and Planning of Radiation Therapy Sarajevo (Bosnia & Hercegovina) Tuesday, June 17 2014 11:40-12:20 a.m María José García Velloso Servicio de Medicina Nuclear Clínica Universidad de Navarra
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationNuclear Medicine in Thyroid Cancer. Phillip J. Koo, MD Division Chief of Diagnostic Imaging
Nuclear Medicine in Thyroid Cancer Phillip J. Koo, MD Division Chief of Diagnostic Imaging Financial Disclosures Bayer Janssen Learning Objectives To learn the advantages and disadvantages of SPECT/CT
More informationto lymph nodes of the neck
[Chinese Journal of Cancer 28:3, 263-267; March 2009]; 2009 Landes Bioscience Clinical Research Paper 18 F-FDG PET/CT for the detection of primary tumors metastasizing to lymph nodes of the neck Ying-Ying
More informationAppendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer
Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph
More informationWhat is head and neck cancer? How is head and neck cancer diagnosed and evaluated? How is head and neck cancer treated?
Scan for mobile link. Head and Neck Cancer Head and neck cancer is a group of cancers that start in the oral cavity, larynx, pharynx, salivary glands, nasal cavity or paranasal sinuses. They usually begin
More informationHead and Neck Cancer. What is head and neck cancer?
Scan for mobile link. Head and Neck Cancer Head and neck cancer is a group of cancers that usually originate in the squamous cells that line the mouth, nose and throat. Typical symptoms include a persistent
More informationUtility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)
Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Poster No.: C-1360 Congress: ECR 2015 Type: Scientific Exhibit Authors:
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationUse of molecular and functional imaging for treatment planning The Good, The Bad and The Ugly
Use of molecular and functional imaging for treatment planning The Good, The Bad and The Ugly Robert Jeraj, PhD Associate Professor of Medical Physics, Human Oncology, Radiology and Biomedical Engineering
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationTitle: TC simulation versus TC/PET simulation for radiotherapy in lung cancer: volumes comparison in two cases.
Title: TC simulation versus TC/PET simulation for radiotherapy in lung cancer: volumes comparison in two cases. Authors: Franzone, P.; 1* Muni, A; 2 Cazzulo, E.; 3 Berretta, L.; 1 Pozzi, G. 1 ; Todisco,
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationThe Proper Use of PET/CT in Tumoring Imaging
The Proper Use of PET/CT in Tumoring Imaging Mijin Yun, M.D. Jong Doo Lee, M.D. Department of Radiology / Division of Nuclear Medicine Yonsei University College of Medicine, Severance Hospital E mail :
More informationNew modalities in the salvage of recurrent nasopharyngeal carcinoma
New modalities in the salvage of recurrent nasopharyngeal carcinoma Dr Jeeve Kanagalingam FRCS Eng (ORL-HNS) Department of Otorhinolaryngology Tan Tock Seng Hospital SINGAPORE Nasopharyngeal carcinoma
More informationPET/CT in breast cancer staging
PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?
More informationROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London
ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London CANCER Key facts Estimated 15.2 million new cases per year in 2015 worldwide
More informationAn Introduction to PET Imaging in Oncology
January 2002 An Introduction to PET Imaging in Oncology Janet McLaren, Harvard Medical School Year III Basics of PET Principle of Physiologic Imaging: Allows in vivo visualization of structures by their
More informationNeck Imaging Reporting and Data System: An Atlas of NI-RADS Categories for Head and Neck Cancer
Neck Imaging Reporting and Data System: An Atlas of NI-RADS Categories for Head and Neck Cancer Bethany Cavazuti Patricia Hudgins Tanya Rath Char Branstetter Kristen Baugnon Amanda Corey Ashley Aiken Disclosures
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationMolecular Imaging and Cancer
Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000
More informationStaging recurrent ovarian cancer with 18 FDG PET/CT
ONCOLOGY LETTERS 5: 593-597, 2013 Staging recurrent ovarian cancer with FDG PET/CT SANJA DRAGOSAVAC 1, SOPHIE DERCHAIN 2, NELSON M.G. CASERTA 3 and GUSTAVO DE SOUZA 2 1 DIMEN Medicina Nuclear and PET/CT
More informationPET SCANS: THE WHO, WHEN AND WHY & HOW TO GET REIMBURSED
PET SCANS: THE WHO, WHEN AND WHY & HOW TO GET REIMBURSED Cecelia E. Schmalbach, MD, FACS Associate Professor of Surgery Head & Neck Surgery Otolaryngology Residency Program Director No Financial Disclosures
More informationRole of positron emission mammography (PEM) for assessment of axillary lymph node status in patients with breast cancer
Role of positron emission mammography (PEM) for assessment of axillary lymph node status in patients with breast cancer Poster No.: C-1260 Congress: ECR 2011 Type: Scientific Paper Authors: K. M. Kulkarni,
More informationEsophageal Cancer. What is the value of performing PET scan routinely for staging of esophageal cancers
Esophageal Cancer What is the value of performing PET scan routinely for staging of esophageal cancers What is the sensitivity and specificity of PET scan for metastatic lesions When should PET scan be
More informationEvaluation of Lung Cancer Response: Current Practice and Advances
Evaluation of Lung Cancer Response: Current Practice and Advances Jeremy J. Erasmus I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of
More informationStaging and restaging for distant metastatic disease in breast cancer: Has anything changed?
Staging and restaging for distant metastatic disease in breast cancer: Has anything changed? Sarah J Vinnicombe Clinical Senior Lecturer in Cancer Imaging Dundee Cancer Centre s.vinnicombe@dundee.ac.uk
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationStereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience.
Stereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience. Elisabetta Ponti MD, Gianluca Ingrosso MD, Alessandra Carosi PhD, Luana
More informationCONTRAST-ENHANCED 18 F-FDG-PET/CT FOR THE ASSESSMENT OF NECROTIC LYMPH NODE METASTASES
ORIGINAL ARTICLE CONTRAST-ENHANCED 18 F-FDG-PET/CT FOR THE ASSESSMENT OF NECROTIC LYMPH NODE METASTASES Stephan K. Haerle, MD, 1 Klaus Strobel, MD, 2 Nader Ahmad, MD, 1 Alex Soltermann, MD, 3 Daniel T.
More informationPositron emission tomography predicts survival in malignant pleural mesothelioma
Flores et al General Thoracic Surgery Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, a Timothy Akhurst, MD, b Mithat Gonen, PhD, c Maureen Zakowski,
More informationLearning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening
Disclosure I, Taylor Rowlett, DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationCombining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
More informationLYMPHATIC DRAINAGE IN THE HEAD & NECK
LYMPHATIC DRAINAGE IN THE HEAD & NECK Like other parts of the body, the head and neck contains lymph nodes (commonly called glands). Which form part of the overall Lymphatic Drainage system of the body.
More informationNoninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index
doi: 10.5761/atcs.oa.14-00241 Original Article Noninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index Satoshi Shiono, MD, 1 Naoki Yanagawa, MD, 2 Masami Abiko,
More informationSquamous cell carcinoma accounts for most of the approximately. Negative Predictive Value of Surveillance PET/CT in Head and Neck Squamous Cell Cancer
ORIGINAL RESEARCH HEAD & NECK Negative Predictive Value of Surveillance PET/CT in Head and Neck Squamous Cell Cancer M. McDermott, M. Hughes, T. Rath, J.T. Johnson, D.E. Heron, G.J. Kubicek, S.W. Kim,
More informationTitle: What is the role of pre-operative PET/PET-CT in the management of patients with
Title: What is the role of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis? Pablo E. Serrano, Julian F. Daza, Natalie M. Solis June
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationResearch Article Planned Neck Dissection Following Radiation Treatment for Head and Neck Malignancy
Hindawi Publishing Corporation International Journal of Otolaryngology Volume 22, Article ID 95423, 5 pages doi:5/22/95423 Research Article Planned Neck Dissection Following Radiation Treatment for Head
More informationORIGINAL ARTICLE. Harold Lau, MD; Tien Phan, MD; Jack MacKinnon, MD; T. Wayne Matthews, MD
ORIGINAL ARTICLE Absence of Planned Neck Dissection for the N2-N3 Neck After Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Harold Lau, MD; Tien Phan, MD; Jack MacKinnon,
More informationThe following images were all acquired using a CTI Biograph
Positron Emission Tomography/ Computed Tomography Imaging of Head and Neck Tumors: An Atlas Michael M. Graham, MD, PhD, and Yusuf Menda, MD Department of Radiology, University of Iowa, Iowa City, IA. Address
More informationPREDICTION OF OUTCOME IN HEAD-AND-NECK CANCER PATIENTS USING THE STANDARDIZED UPTAKE VALUE OF 2-[ 18 F]FLUORO-2-DEOXY-D-GLUCOSE
doi:10.1016/j.ijrobp.2003.12.039 Int. J. Radiation Oncology Biol. Phys., Vol. 59, No. 5, pp. 1295 1300, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationMathieu Hatt, Dimitris Visvikis. To cite this version: HAL Id: inserm
Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography: still a Pandora s box?: in regard to Devic et al. (Int J Radiat Oncol Biol Phys 2010).
More informationAustin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate)
Austin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate) Overview Ga-68 dotatate binds to somatostatin receptors, with highest affinity for subtype 2 receptors (sstr2). It binds to cells that express
More informationRadiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer
Radiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer Poster No.: C-0654 Congress: ECR 2011 Type: Scientific Paper Authors:
More informationAssessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose
Assessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose Poster No.: C-0805 Congress: ECR 2015 Type: Scientific Exhibit Authors: S. Ito, K. Kato,
More informationMolecular Imaging and Breast Cancer
Molecular Imaging and Breast Cancer Breast cancer forms in tissues of the breast usually in the ducts, tubes that carry milk to the nipple, and lobules, the glands that make milk. It occurs in both men
More informationComparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer
Original Article Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer Gil-Su Jang 1 *, Min-Jeong Kim 2 *, Hong-Il Ha 2, Jung Han Kim
More informationSetting The setting was outpatient (ambulatory patients). The economic study was carried out in France.
Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer Lejeune C, Bismuth M J, Conroy T, Zanni C, Bey P,
More informationPET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
More informationFluorodeoxyglucose Positron Emission Tomography in the Evaluation of Tumors of the Nasopharynx, Paranasal Sinuses, and Nasal Cavity
Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Tumors of the Nasopharynx, Paranasal Sinuses, and Nasal Cavity Brendan C. Stack, Jr, MD, FACS * Val J. Lowe, MD Robert V. Lane, MD *
More informationImaging Surveillance in Women with a History of Treated Breast Cancer. Wei Tse Yang, M.D.
Imaging Surveillance in Women with a History of Treated Breast Cancer Wei Tse Yang, M.D. Breast Cancer 1. Extent 2. Response 3. Recurrence Surveillance Breast Cancer 1. Extent 2. Response Surveillance
More information8/10/2016. PET/CT for Tumor Response. Staging and restaging Early treatment response evaluation Guiding biopsy
PET/CT for Tumor Response Evaluation August 4, 2016 Wei Lu, PhD Department of Medical Physics www.mskcc.org Department of Radiation Oncology www.umaryland.edu FDG PET/CT for Cancer Imaging Staging and
More informationNew Visions in PET: Surgical Decision Making and PET/CT
New Visions in PET: Surgical Decision Making and PET/CT Stanley J. Goldsmith, MD Director, Nuclear Medicine Professor, Radiology & Medicine New York Presbyterian Hospital- Weill Cornell Medical Center
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationPet Scan And Gynaecological Malignancies: Hospital Sultanah Bahiyah Experience
ORIGINAL ARTICLE Pet Scan And Gynaecological Malignancies: Hospital Sultanah Bahiyah Experience T Shahila, MMED (O&G), M N Rushdan, MMED (O&G) Gynaecological Oncology Unit, Department of Obstetrics & Gynaecology,
More informationChapter 2. FDG PET Imaging of Head and Neck Cancers. Yusuf Menda and Michael M. Graham. Abstract. 1. Introduction
Chapter 2 FDG PET Imaging of Head and Neck Cancers Yusuf Menda and Michael M. Graham Abstract In initial staging of head and neck cancers, the addition of FDG PET to conventional imaging improves the accuracy
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationHead and Neck Service
Head and Neck Service University of California, San Francisco, Department of Radiation Oncology Residency Training Program Head and Neck and Thoracic Service Educational Objectives for PGY-5 Residents
More informationBiases affecting tumor uptake measurements in FDG-PET
Biases affecting tumor uptake measurements in FDG-PET M. Soret, C. Riddell, S. Hapdey, and I. Buvat Abstract-- The influence of tumor diameter, tumor-tobackground activity ratio, attenuation, spatial resolution,
More informationFDG-PET Findings in an Ovarian Endometrioma: A Case Report
FDG-PET Findings in an Ovarian Endometrioma: A Case Report Jia-Huei Lin 1, Victor Chit-kheng Kok 2, Jian-Chiou Su 3 1 Department of Nuclear medicine, Kuang Tien General Hospital, Sha-Lu, Taichung, Taiwan
More informationWhen do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
More informationPET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany
PET-MRI in malignant bone tumours Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to PET/MRI General considerations Bone metastases Primary bone tumours
More informationPET-CT for radiotherapy planning in lung cancer: current recommendations and future directions
PET-CT for radiotherapy planning in lung cancer: current recommendations and future directions Gerry Hanna Centre for Cancer Research and Cell Biology Queen s University of Belfast @gerryhanna Talk Outline
More informationTriage of Limited Versus Extensive Disease on 18 F-FDG PET/CT Scan in Small Cell lung Cancer
Triage of Limited Versus Extensive Disease on F-FDG PET/CT Scan in Small Cell lung Cancer Riaz Saima 1*, Bashir Humayun 1, Niazi Imran Khalid 2 1 Department of Nuclear Medicine, Shaukat Khanum Memorial
More informationUltrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer
Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Its Not Just About the Nodes AACE Advances in Medical and Surgical Management of Thyroid Cancer - 2017 Robert A. Levine, MD,
More informationMolecular Imaging and the Brain
Molecular imaging technologies are playing an important role in neuroimaging, a branch of medical imaging, by providing a window into the living brain. Where CT and conventional MR imaging provide important
More information18F-FDG Positron Emission Tomography CT (FDG PET-CT) in the Management of Pancreatic Cancer: Initial Experience in 12 Patients
18F-FDG Positron Emission Tomography CT (FDG PET-CT) in the Management of Pancreatic Cancer: Initial Experience in 12 Patients Muhammad Wasif Saif 1, Daniel Cornfeld 1, Houmayoun Modarresifar 2, Buddhiwardhan
More informationPET/CT in Breast Cancer
PET/CT in Breast Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria Overview Introduction Locorregional
More informationEfficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced
Eur J Nucl Med Mol Imaging (2017) 44:581 588 DOI 10.1007/s00259-016-3537-8 ORIGINAL ARTICLE Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome
More informationTypical PET Image. Elevated uptake of FDG (related to metabolism) Lung cancer example: But where exactly is it located?
Typical PET Image Elevated uptake of FDG (related to metabolism) Lung cancer example: But where exactly is it located? PET/CT Oncology Imaging Anatometabolic fusion images are useful in the management
More informationTHE EFFECT OF USING PET-CT FUSION ON TARGET VOLUME DELINEATION AND DOSE TO ORGANS AT RISK IN 3D RADIOTHERAPY PLANNING OF PATIENTS WITH NSSLC
THE EFFECT OF USING PET-CT FUSION ON TARGET VOLUME DELINEATION AND DOSE TO ORGANS AT RISK IN 3D RADIOTHERAPY PLANNING OF PATIENTS WITH NSSLC Hana Al-Mahasneh,M.D*., Mohammad Khalaf Al-Fraessan, M.R.N,
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Carcinoma of unknown primary origin (CUP) Faculty of Clinical Radiology www.rcr.ac.uk Contents Carcinoma of
More information